BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGUANGZHOU, China ---(Businesswire)--- Bio-TheraSolutions, Ltd (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and a pipeline of biosimilars,today announced the company has entered into a licensing and supply agreement with BiommSA, for BAT 22 06...
GUANGZHOU, CHINA, April 14, 2023 – Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced the company will present one poster concerning Phase 1 clinicalresults for BAT1006 at the 2023 American Association for Cancer Research("AACR") Annual Meeting taking ...
Guangzhou, China --(BUSINESSWIRE)-- Bio-TheraSolutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, todayannounced that dosing has begun in a Phase 1 clinical study evaluating BAT8007,an antibody-drug conjugate (ADC) that targets Nectin-4. The multicenter,open-label Phase 1 clinica...